Dr. Reddy’s details March 2026 investor meetings
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its upcoming schedule of analyst and institutional investor meetings. The company’s management plans to participate in two group meetings with investors in early March 2026.
On March 4, 2026, management will attend an in-person group meet organized by Ambit Capital in Hyderabad from 11:00 to 13:30 IST. On March 5, 2026, they will join a virtual group meet organized by Goldman Sachs from 11:15 to 12:15 IST. The company notes that this schedule may change due to any exigencies on the part of investors or the company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Dr. Reddy’s Laboratories (RDY) disclosing in this Form 6-K?
When and where are Dr. Reddy’s (RDY) investor meetings scheduled in March 2026?
Who is organizing the upcoming Dr. Reddy’s (RDY) analyst and investor conferences?
What is the format of Dr. Reddy’s (RDY) March 2026 analyst and investor meetings?
Can the schedule of Dr. Reddy’s (RDY) analyst and investor meetings change?
Which stock exchanges list Dr. Reddy’s Laboratories referenced in this disclosure?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
February, 2026
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ___________
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ___________
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-___________.
EXHIBITS
Exhibit |
| Description of Exhibits |
|
|
|
99.1 | Intimation dated February 27, 2026 |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED (Registrant) | ||
|
| ||
Date: February 27, 2026 | By: | /s/ K Randhir Singh | |
|
| Name: | K Randhir Singh |
|
| Title: | Company Secretary |
| 3 |
Exhibit 99.1
| Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India
CIN: L85195TG1984PLC004507
Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com |
February 27, 2026
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings
This is to inform that the Company’s management will be participating in the following investor conference with single institution(s)/ investor groups:
Date | Organized by | Location | Meeting mode | Nature of meet | Timing |
04.03.2026 | Ambit Capital | Hyderabad | In-Person | Group Meet | 11:00 - 13:30 IST |
05.03.2026 | Goldman Sachs | - | Virtual | Group Meet | 11:15 - 12:15 IST |
Please note that the schedule of the aforesaid meeting is subject to change due to any exigencies on the part of Investors / Company.
This is for your information.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh